Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Blood Adv · 2025 · PMC12405623 · PMID 40554413

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

9 There was a clear trend toward increasing levels of blood B cells with declining tisagenlecleucel transgene levels. 1 In this setting, most patients had ongoing responses despite having BCR within the normal range.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.